top of page
  • Patient Education

Patient Education: Ciltacabtagene Autoleucel - Carvykti - (CART Cell Therapy) - Immunotherapy

Updated: Mar 27, 2022

Patient Education: Ciltacabtagene Autoleucel

https://www.carvykti.com


CILTA CEL CART Cell therapy Multiple Myeloma


Ciltacabtagene Autoleucel ( Carvykti)


FDA approves ciltacabtagene autoleucel for relapsed or refractory multiple myeloma


On February 28, 2022, the Food and Drug Administration approved ciltacabtagene autoleucel (CARVYKTI, Janssen Biotech, Inc.) for the treatment of adult patients with relapsed or refractory multiple myeloma after four or more prior lines of therapy, including a proteasome inhibitor (PI), an immunomodulatory agent (IMiD), and an anti-CD38 monoclonal antibody.


Safety and efficacy were evaluated in CARTITUDE-1 (NCT03548207), an open label, multicenter clinical trial evaluating ciltacabtagene autoleucel in 97 patients with relapsed or refractory multiple myeloma who received at least three prior lines of therapy which included a PI, an IMiD, and an anti-CD38 monoclonal antibody and who had disease progression on or after the last chemotherapy regimen; 82% had received four or more prior lines of antimyeloma therapy.


Learn more:

Click here to learn more

 

Information on Carvykti website

https://www.carvykti.com

 

INTERNATIONAL MYELOMA FOUNDATION:


CARVYKTI (ciltacabtagene autoleucel)

https://www.myeloma.org/treatment/carvykti-ciltacabtagene-autoleucel


IMF Understanding Series

https://www.myeloma.org/cancer-information-series


IMF Resource Library

https://www.myeloma.org

https://www.myeloma.org/publications-videos

https://www.youtube.com/c/IMFMyeloma/videos


Current FDA-Approved Medications for Multiple Myeloma Treatment

https://www.myeloma.org/multiple-myeloma-drugs

 

HEALTH TREE UNIVERSITY MYELOMA:


Janssen's Cilta-Cel CAR T Receives FDA Approval for Relapsed Multiple Myeloma

Learn more


HealthTree University for Multiple Myeloma Lectures

https://healthtree.org/myeloma/university/courses

https://healthtree.org/


Health Tree University Myeloma Videos

https://www.youtube.com/c/HealthTreeUniversity/videos

 

MULTIPLE MYELOMA RESERACH FOUNDATION:


Standard Treatments - BCMA-directed personalized immunotherapy - ciltacabtagene autoleucel or cilta-cel - Carvykti

https://themmrf.org/multiple-myeloma/treatment-options/standard-treatments/carvykti/

https://themmrf.org/multiple-myeloma/treatment-options/standard-treatments/


MMRF Education Programs

https://themmrf.org/resources/education-programs/

https://themmrf.org/


MMRF Videos

https://www.youtube.com/user/TheMMRF/videos

 

References CARVYKTI- ciltacabtagene autoleucel injection, suspension:


FDA Label Prescribing Information (Revised 03/2022)

Prescribing Information | CARVYKTI


Medication Guide


Drug Label Information at DAILYMED - NIH-National Library of Medicine

DailyMed - CARVYKTI- ciltacabtagene autoleucel injection, suspension


Other Resources

Resources & Support

 



- Multiple Myeloma Patient Education & Information on ongoing Multiple Myeloma Clinical Trials -

Posts Archive
bottom of page